Invetx Raises $15 Million from Anterra, AbCellear and WuXi Biologics
publication date: Feb 24, 2020
Invetx of Boston, an animal health biologics company, announced a $15 million Series A financing led by Anterra of Boston and joined by two Invetx collaborators, AbCellear and WuXi Biologics. AbCellular is a Vancouver-based company that discovers biotech candidates for partners. WuXi Biologics, a global biologic CDMO based in China, will collaborate with Invetx on development and manufacturing. Invetx plans to apply the breakthroughs of biotechnology to animal health. Its team, which combines staff with human biotech and animal health experience, expects the company will start its first clinical trial this year. More details...
Stock Symbol: (HK: 2269)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.